Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells

Scientific progress often follows a prolonged path, but bioentrepreneur Samy Lamouille believes his dedication toward this pursuit will ultimately pay off for brain cancer patients.

November 22, 2024

Vol.50 No.44

In Brief

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

RAS-mutant leukemia stem cells behave differently from other leukemia stem cells

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia and its resistance to a common treatment. The study, published Oct. 30 in Nature, was led by Eirini Papapetrou, professor of oncological sciences at Icahn Mount Sinai. Acute myeloid leukemia is a devastating blood cancer that starts in...

November 08, 2024

Vol.50 No.42

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

YOU MAY BE INTERESTED IN

UVA Health tests focused ultrasound to increase immune response in melanoma

Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

RAS-mutant leukemia stem cells behave differently from other leukemia stem cells

Renew today!

Subscriber content

Never miss an issue!

Login